Biointron’s Q2 2026 Antibody Industry Trends report aims to explore the events and trends of the biopharmaceutical industry in April, May, and June. This quarter, six novel monoclonal antibody drugs have received first approval.
The first wave of antibody drugs against COVID-19 showed both the promise and the limitations of this form of treatment. Researchers are now exploring ways to develop antibodies that remain effective against a wider range of variants, while also using artificial intelligence to analyze viral evolution and guide protein design.
TED is a rare, debilitating disease that can cause eye dryness and redness, eyelid swelling or retraction, bulging eyes (proptosis), double vision, and, in severe cases, vision impairment.
Time: April 15 - 19, 2026
Location: Boston, MA
Booth: #1228
Time: April 28 – 30, 2026
Location: Seoul, South Korea
Booth: #B31
Time: May 9 - 10, 2026
Location: Boston, MA
AI is transforming antibody discovery, but better models only come from better data. When you are generating and screening sequences at scale, you need characterization results that are fast, comprehensive, and ready to use without hours of cleanup and reformatting.
The antibody therapeutics sector is rapidly evolving, transitioning from traditional hybridoma methods to single B and AI-driven de novo design approaches, significantly compressing discovery timelines and creating novel binding moieties.
Biointron’s 2026 Lunch & Learn, held at CIC Cambridge on May 8, 2026, featured expert presentations from SeromYx Systems and Visterra on two critical areas of antibody and biologic development: Fc-effector function profiling and cell-based neutralizing antibody (NAB) assay design.
When you’re a small biotech with big ambitions, every week counts. For Macomics Limited, that meant finding a way to get high-quality antibodies quick···
The demand for fully human therapeutic antibodies continues to grow, driving the need for more efficient discovery platforms.
Case 1: Tag-Free Vaccine Protein. During the generation of stable cell lines, cells are selected and screened to identify clones that stably express t···
Apply for Biointron's Quarterly Travel Grant. Receive $800 to support early-career antibody researchers in attending scientific conferences, symposia, and workshops.
Submit a quick Biointron testimonial and we’ll send you a $25 Amazon gift card. Simple, fast, and appreciated!
Get 25% off your next Biointron project when you cite us in your paper!
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This month in June, we'll highlight the era of AI-driven antibody discovery.
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This month in May, we'll highlight the future of VHH technology, chemical conjugation in antibody therapeutics, and emerging trends in antibody characterization.
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This month in April, we'll highlight ATP-dependent switch antibodies, the throughput-quality gap in antibody discovery, and multiple myeloma antibody treatments.
For an antibody candidate, strong target binding is only part of the path toward a successful therapeutic. A molecule can show high affinity and selectivity yet encounter problems later because of poor stability, low expression, aggregation, non-specific binding, or other unfavorable biophysical properties.
Explore VHH-based biosensors for high-sensitivity detection using nanobodies in electrochemical, SPR, and optical diagnostic platforms.
Biointron’s Antibodies After Hours: BIO 2026 Reception was held at The Lion's Share in San Diego on Tuesday, June 23, 2026. Held on the second day of the BIO International Convention, we had a memorable evening of networking, drinks, and delicious appetizers with members of the biotech and pharma community at one of San Diego’s most distinctive downtown venues!
You can also contact us on the Scientist and Science Exchange marketplaces.
